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Morbidity caused by early allograft dysfunction, manifested by a progressive 
increase in pulmonary vascular resistance and a decrease in oxygenation, 
remains a serious problem in lung transplantation. I halation of nitric oxide, 
an essential homeostatic molecule, has been shown to have beneficial effects on 
a variety of acute lung injuries. The purpose of the present study was to 
investigate the effect of inhaled nitric oxide on posttransplant function of 
canine left lung allografls. Fourteen dogs underwent left lung aUotransplan- 
tation. Donors received systemic heparin and prostaglandin E1 followed by 
pulmonary artery flush with modified Euro-Collins solution. Donor left lungs 
were stored for 18 hours at I°C and subsequently implanted. Immediately 
after reperfusion, the contralateral right main pulmonary artery and bronchus 
were ligated. The chest was closed and recipients turned to the supine position 
for the 6-hour assessment period. Hemodynamic and arterial and venous 
blood gas analyses were made at 15-minute intervals at an inspired oxygen 
fraction of 1.0 and 5 cm of water positive end-expiratory pressure. Animals 
were killed at the end of the assessment. Allograft myeloperoxidase activity 
assays and wet/dry weight ratios were done. In group I (n = 5), nitric oxide gas 
was administered continuously at concentrations of 60 to 70 ppm before 
reperfusion and throughout the 6-hour assessment period. In group II (n = 5), 
nitric oxide administration was initiated at the same concentration after 
reperfusion i jury had developed. Group HI animals (n = 4) received no nitric 
oxide. Significant improvement in gas exchange was pparent in group I. At the 
end of the 6-hour assessment period, mean arterial oxygen tension was 253.8 
- 44.7 mm Hg and 114.9 -+ 25.5 mm Hg in groups I and HI, respectively (p < 
0.05). Group II animals had no improvement in oxygenation with nitric oxide. 
Systemic hemodynamics were unaffected by nitric oxide. However, an imme- 
diate decrease in pulmonary vascular esistance was noted. Group I myelo- 
peroxidase activity was significantly lower than that in control group HI (0.24 
- 0.06 versus 0.36 - 0.04 units, respectively; p < 0.05). (J Thorac Cardiovasc 
Surg 1996;112:293-9) 
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k ung transplantation has become a successful strategy for the treatment of a variety of end- 
stage lung diseases. The results of lung transplanta- 
tion now equal those of other solid organs. How- 
ever, early postoperative allograft dysfunction 
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remains a common and unpredictable problem. This 
transient allograft dysfunction, sometimes severe, is 
accompanied by an increase in pulmonary artery 
pressure and poor gas exchange. 1 
Nitric oxide (NO) is a potent endogenous medi- 
ator produced by a variety of cells including vascular 
endothelium and is believed to be identical to the 
endothelium-derived relaxing factor. 2' 3 Nitric oxide 
has been shown to have many physiologic properties 
that play an important role in the maintenance of 
vascular homeostasis, < 5 neurotransmission, and im- 
mune function. 6NO is known to be a potent vasodi- 
lator and a potent inhibitor of platelet aggregation 3' 7
and adhesion. 8 NO also has potent antineutrophil 
activity that includes the inhibition of neutrophil ag- 
gregation 9 and neutrophil adhesion. 1°' n Furthermore, 
it was demonstrated recently that NO modulates mi- 
crovascular permeability and that when NO produc- 
tion by the endothelium is diminished, vascular per- 
meability is dramatically increased. 12 
Inhalation of NO gas in concentrations of 5 to 80 
ppm has been shown, in animals and human beings, 
to produce significant pulmonary vasodilation with- 
out causing systemic vasodilation, 13 even in the 
presence of pulmonary endothelial injury. 14 NO is 
inactivated rapidly by binding with high affinity to 
hemoglobin. Therefore inhaled NO results in pul- 
monary vasodilation limited to ventilated regions of 
lung. In patients with acute lung injury such as acute 
respiratory distress syndrome, inhalation of low- 
concentration NO selectively improves the perfu- 
sion of ventilated alveoli, resulting in an improve- 
ment of pulmonary gas exchange, is 
This study was undertaken to investigate whether 
inhalation of NO, administered before and after 
reperfusion injury at a concentration of 60 to 70 
ppm, would decrease ischemia-reperfusion lu g in- 
jury in an 18-hour preserved canine lung allograft 
model. 
Material and Methods 
Adult conditioned mongrel dogs were studied. All 
animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Donor procedure. Donor animals were anesthetized 
with intravenous thiopental sodium (10 mg/kg), followed 
by atropine (0.5 mg), and intubated with an endotracheal 
tube (outer diameter 9 mm). Mechanical ventilation was 
established (Bennett MA1, Puritan Bennett, Inc., Over- 
land Park, Kan.) with 100% oxygen at a tidal volume of 
20 ml/kg, a rate of 12 breaths/min, and with a positive 
end-expiratory pressure of 5 cm H20. After a median 
sternotomy, the superior and inferior vena cavae, the 
ascending aorta, the main pulmonary artery, and the 
trachea were isolated. Animals were heparinized (400 
U/kg) before insertion of a curved metal-tipped cannula 
(Sarns, Inc., Ann Arbor, Mich.) through a purse-string 
suture in the main pulmonary artery. Before the admin- 
istration of flush solution, 250/xg prostaglandin E 1 (Pros- 
tin VR Pediatric, The Upjohn Company, Kalamazoo, 
Mich.) was injected directly into the main pulmonary 
artery. Cardiac inflow was occluded by ligation of the 
superior and inferior vena cavae 20 seconds after the 
infusion of prostaglandin El. The proximal inferior vena 
cava was cut and the tip of the left atrium was excised for 
decompression of the pulmonary artery flush. Immedi- 
ately, the lungs were perfused at a pressure of 40 cm H20 
with 50 ml/kg of cold (1 ° C) Euro-Collins solution, mod- 
ified by the addition of 4 mmol/L MgSO 4 and 32.7 gm/L 
glucose. During the flush the lungs were also topically 
cooled by flooding the chest with cold (1 ° C) saline 
solution. When the flush was completed, the trachea was 
clamped at end-inspiration and the heart-lung block ex- 
cised. The harvested organs were placed in plastic bags 
containing cold (4 ° C) modified Euro-Collins olution and 
stored in ice slush. Lungs were removed from storage 
immediately before implantation at a time to coincide 
with a total ischemic time of 18 hours. 
Recipient procedure. Recipient animals were anesthe- 
tized in the same manner as the donors and the lungs 
ventilated with an adjustable-rate Harvard pump respira- 
tor (model 613, Harvard Apparatus, South Natiek, Mass.) 
with 98.5% oxygen and 1.5% halothane. A right femoral 
arterial line and Swan-Ganz catheter (Baxter Healthcare 
Corp., Edwards Division, Santa Ana, Calif.) were placed 
and continuously transduced (model 1290A, Hewlett- 
Packard, Andover, Mass.). After left thoracotomy, a 
wedge resection of the recipient's native left lung was 
taken as a control sample for myeloperoxidase activity 
assay (described later). The contralateral main pulmonary 
artery and upper and lower bronchus were mobilized and 
encircled separately with umbilical tapes. Left pneumo- 
nectomy was then done. 
The donor left lung was separated from the heart-lung 
block. Left single-lung allotransplantation was done as 
16 previously described. The lung was kept cold with 
crushed ice during implantation. The left atrial anastomo- 
sis was done first with a continuous everting mattress 
suture. Continuous over-and-over suture was used for 
both pulmonary artery and bronchus. After completion of 
these anastomoses, the left lung was reperfused after 
removal of air. A Millar pressure transducer (Millar 
Instruments, Inc., Houston, Tex.) was placed in the left 
atrium and two chest ubes were inserted. The contralat- 
eral right bronchial tapes were firmly tied, and airway 
occlusion was confirmed with a fiberoptic bronchoscope. 
Subsequently the contralateral right pulmonary artery was 
ligated. At this point, the ventilator was changed to a 
Bennett model MA1 (Puritan-Bennett, Carlsbad, Calif.) 
with 100% oxygen at a tidal volume of 550 ml, a rate of 20 
breaths/min, and 5 cm of water positive end-expiratory 
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pressure. The chest was closed with skin staples and the 
animals turned to the supine position for a 6-hour assess- 
ment period. 
It is apparent that different anesthesia techniques were 
used for donors and recipients. For lengthy implantation 
procedures a gas anesthesia technique was required and 
the Harvard ventilator (Harvard Apparatus, Inc., Natick, 
Mass.) was connected to a gas blender. For the shorter 
donor procedure and for subsequent recipient assess- 
ments (described later), an intravenous anesthetic tech- 
nique was sufficient. However, precise control of inspired 
oxygen fraction and positive end-expiratory pressure lev- 
els was required and, for that reason, a Bennett MA1 
ventilator was used. 
Study groups. Fourteen dogs were allocated randomly 
to three groups. In group I (n = 5), NO gas was 
administered continuously at concentrations of 60 to 70 
ppm before reperfusion throughout the 6-hour assessment 
period. In group II (n = 5), NO was administered to the 
recipient dogs at the same concentration asthat in group 
I. For group II animals NO therapy was initiated after 
reperfusion injury was established. For purposes of this 
study, this point occurred when the ratio of arterial oxygen 
tension (Pao2) to inspired oxygen fraction fell below 150 
or after 3 hours of assessment, whichever came first. 
Group III animals (n = 4) received no NO. 
Gas administration. In group I animals NO adminis- 
tration was initiated 10 minutes before reperfusion. The 
NO/N2 gas mLxture (2200 ppm NO in pure N2) (Scott 
Medical Products, Plumsteadville, Pa.) was administered 
directly into the inspiratory limb of the respirator circuit, 
about 50 cm proximal to the endotracheal tube. Inspired 
NO and nitrous dioxide (NO2) concentrations were con- 
tinuously measured just proximal to the endotracheal tube 
with the use of chemiluminescence analyzers (model 
AR-PRN-1, B & W Technologies, Calgary, Alberta, Can- 
ada) and were: recorded every 15 minutes. NO 2 concen- 
tration was kept less than 4 ppm. 
Measurements. After repositioning of the animals to 
the supine position just after skin closure, the 6-hour 
assessment period was started. During this time, anesthe- 
sia was maintained with intravenous administration of 
thiopental sodium. Systemic arterial, pulmonary arterial, 
central venous, and left atrial pressures were continuously 
recorded throughout the assessment period. Cardiac out- 
put was determined hourly (model 9520, Edwards Labo- 
ratories, Inc., Santa Ana, Calif.). Arterial and mixed 
venous blood were collected for gas analysis every 15 
minutes. Sodium bicarbonate was infused intravenously as
necessary to maintain pH in physiologic range. Intrave- 
nous Ringer's lactate solution was administered through- 
out the surgical procedure and assessment in the recipi- 
ent. Alveolar arterial oxygen difference (A-aDo2) and 
pulmonary vascular resistance (PVR) were determined 
hourly as follows: 
A-aDo 2 (turn Hg) = barometric pressure - water vapor 
pressure - Arterial carbon dioxide tension (Paco2) - Pao 2 
PVR (dynes/sec/cm -5) = (mean pulmonary artery pres- 
sure - left atrial pressure)/cardiac index × 79.9 
Airway edema fluid from the left lung was collected via 
fiberoptic bronchoscope 10 minutes before each arterial 
blood gas assessment, and the total suction volume for the 
6-hour assessment period was measured. After the final 
measurement, the animals were killed and both lungs 
were submitted to histologic examination, tissue myelo- 
peroxidase assay, and wet/dry weight ratio measurement. 
Quantitative morphometric assessment was not used. 
At the final blood sampling, venous blood samples were 
obtained from three animals in each group for measure- 
ment of methemoglobin. 
Myeloperoxidase assay. Each donor and recipient lung 
sample was immediately frozen by immersing it in dichlo- 
rodifluoromethane (CC12F2) that had been precooled to 
the freezing point. Samples were subsequently stored at 
-70 ° C until assay. Quantitative myeloperoxidase activity 
was determined as previously described. 17 Briefly, 100 mg 
of frozen lung tissue was homogenized in 1 ml of 0.5% 
hexadecyltrimethylammonium bro ide, 5 mmol/L ethyl- 
enediaminetetraacetic acid, and 50 mmol/L potassium 
phosphate buffer (pH 6.2) with a Broeck tissue grinder 
(Kontes Glass Co., Vineland, N.J.). Hexadecyltrimethyl- 
ammonium bromide is a detergent that releases myelo- 
peroxidase from the primary granules of the neutrophil. 
The homogenate was centrifuged at 10,000 g for 15 
minutes at 4 ° C. The supernatant was subsequently as- 
sayed for total soluble protein by the method of Pierce 
Laboratories is and for myeloperoxidase activity. Myelo- 
peroxidase activity was measured spectrophotometrically: 
10 /xl of fivefold supernatant was combined with 0.6 ml 
Hanks bovine serum albumin (0.255 bovine serum albu- 
min added to Hanks solution), 0.5 ml of 100 mmol/L 
potassium phosphate buffer (pH 6.2), 0.1 ml 0.05% HzO2, 
and 0.1 ml of 1.25 mg/ml o-dianisidine. Color develop- 
ment was stopped by addition of 0.1 ml of 1% N after 5 
minutes and after 20 minutes at room temperature. Then 
the optical density was measured at 460 nm with a 
spectrophotometer (model PMQ II, Carl Zeiss, Munich, 
Germany). The color development from 5 minutes to 20 
minutes was linear. One unit of enzyme activity was 
defined as the amount of 1.0 optical density unit per 
minute per milligram of tissue protein at room tempera- 
ture. 
Statistical analysis. All values are given as the mean 
plus or minus standard error of the mean and were 
analyzed by means of the StatView 4.0 statistical system 
(Abacus Concepts, Berkeley, Calif.). One-way analysis of 
variance was used to compare dependent variables among 
three groups. Scheffe's probability testing was used for 
post hoc comparisons. Differences in blood gas and he- 
modynamic data were compared between groups at each 
time point by analysis of variance. Changes in blood gas 
and hemodynamic data within groups over time were 
assessed by repeated-measures analysis of variance. Dif- 
ferences were considered significant at thep < 0.05 level. 
Results 
As expected, there were no significant differences 
between groups regarding donor weight, recipient 
weight, flushing time, preservation time, and warm 
ischemic time (Table I). The mean concentrations of
NO and NO 2 were similar in study groups I and II. 
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Fig. 1. Pao2, Paco 2, and A-aDo 2 for NO administration 
groups (immediate Use for group I and delayed use for 
group II) and control group (group III) through 6-hour 
assessment period. There is significant difference (p < 
0.05) between group I and III in Pao 2 and A-aDo 2 
exchange over time. NS, Not significant. 
Gas exchange. Throughout the 6-hour assess- 
ment period, oxygenation i  group I animals was 
superior to that in other groups (Fig. 1). This 
difference between group I and control group III 
reached statistical significance after 90 minutes. The 
mean Pao 2 at 120 minutes in group I was 435.6 + 
22.2 mm Hg versus 285.2 + 16.0 mm Hg (p < 0.01) 
in the control group. At 360 minutes mean Pao 2 for 
group I was 253.8 _+ 44.7 mm Hg versus 114.9 _+ 25.5 
mm Hg in group III. Pao 2 of the delayed NO 2 
administration group (group II) did not have any 
statistical difference from that in the control group 
at any time. There was no statistical significance in 
Paco2 values between groups. The A-aDo 2 followed 
the same time course as Pao 2 and revealed statistical 
significance between groups I and III (Fig. 1). 
Table L Characteristics of experimental groups 
Group I Group H Group III 
Donor weight (kg) 28.6 ± 1.1 27.7 ± 2.1 28.1 ± 0.8 
Recipient weight (kg) 28.9 ± 1.9 28.3 ± 0.9 28.5 ± 0.8 
Flushing time (sec) 87.8 -+ 14.7 95.2 _+ 10.1 94.9 ± 13.0 
Warm ischemic 53 ± 0.9 55 ± 2.1 53 _+ 4.1 
time (rain) 
Preservation time (hr) 17:30 _+ 0:33 17:25 ± 0:12 17:28 _+ 0:17 
Mean NO 66.3 _+ 2.1 64.9 ± 3.0 - -  
concentration (ppm) 
Mean NO2 3.8 -+ 0.2 3.1 _+ 0.4 - -  
concentration (ppm) 
Hemodynamics. There were no significant differ- 
ences among the three groups in aortic pressure and 
cardiac index throughout the 6-hour study period. 
There were significant differences regarding mean 
pulmonary artery pressure and PVR during the 
assessment period between groups I and III. Al- 
though group II PVR did decrease with NO therapy, 
there was no significant difference between group II 
and other groups (Fig. 2). 
Wet/dry weight ratio. Allograft wet to dry weight 
ratios were similar among the three groups (Fig. 3). 
Suction fluid volume. There was no significant 
difference among the three groups as to total vol- 
ume of allograft edema fluid aspirated uring the 
assessment period (Fig. 3). 
Myeloperoxidase activity assay. There was a sig- 
nificant difference in myeloperoxidase activity be- 
tween group I and group III (0.245 _+ 0.027 units 
versus 0.365 _+ 0.03 units; p < 0.05). However, there 
was no difference between group II (0.308 _+ 0.037 
units) and group III (Fig. 4). 
Methemoglobin. Although the sampling number 
was small (n = 3 in each group), there were no 
significant differences between groups with respect 
to whole blood methemoglobin levels (1.06% _+ 
0.55%, 1.12% _+ 0.11%, and 0.91% -+ 0.24% for 
groups I, II, and iII, respectively). 
Histology. No significant difference in histologic 
findings was noted among the grafts in the three 
groups. The lung showed varying degrees of edema 
formation and emphysematous changes after the 
6-hour assessment period. 
Discussion 
Numerous tudies have been undertaken to im- 
prove the quality of lung allograft preservation and 
limit reperfusion injury. Pathophysiologic mecha- 
nisms of reperfusion injury still are unclear, hut the 
studies regarding the role of leukocytes, platelets, 
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Fig. 2. Aortic pressure (AoP), cardiac index (C.L), mean 
pulmonary arterial pressure (PAP), and PVR for NO 
inhalation groups (immediate use for group I and delayed 
use for group II) and control group (group III) through 
6-hour assessment. There are no differences in systemic 
hemodynamics (aortic pressure and cardiac index) be- 
tween three groups. However, there is statistical signifi- 
cance between groups ! and III in pulmonarY hemody- 
namics (pulmonary arterial pressure and PVR) over time. 
oxygen free radicals, and cytokines have contributed 
to our understanding of the complex mechanisms 
involved. 19-24 It is now recognized that the neutro- 
phil plays an important role in acute lung injury 
associated with ischemia and reperfusion. We have 
previously reported that pentoxifylline, which has 
not only microcirculatory benefits but also antineu- 
trophil effects, reduces canine lung allograft reper- 
fusion injury. 25 We have also reported that a com- 
bination of adhesion molecule monoclonal 
antibodies designed to limit neutrophil adhesion 
attenuates the reperfusion injury in rat lung 
isografts. 26 
In this report, we have demonstrated a significant 
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three groups. 
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Fig. 4. Results of myeloperoxidase activity assay of lung 
tissue after 6-hour assessment. Normal means fresh left 
lung tissue sampled just after thoracotomy. There is 
significant difference between groups I and III. However, 
there is no statistical difference between groups II and III. 
NS, Not significant. 
improvement in Pao 2 and neutrophil sequestration 
of the lung allograft when NO was administered 
before reperfusion. However, delayed NO adminis- 
tration after reperfusion injury was established had 
no effect. Additionally, immediate administration of
NO gas resulted in significant reduction of pulmo- 
nary artery pressure and resistance. It is generally 
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recognized that inhaled NO will modify ventilation- 
perfusion relationships by dilating vessels of venti- 
lated regions of the lung. Apart from the docu- 
mented effect of inhaled NO as a pulmonary 
vasodilator, there are three other possible mecha- 
nisms by which immediate inhalation of NO en- 
hanced the function of reperfused canine lung al- 
lografts. 
First, NO has been shown to be an endogenous 
inhibitor of leukocyte chemotaxis, adherence, and 
activation. TM Adherence of neutrophils to the en- 
dothelium is thought to be the essential step in 
diapedesis of leukocytes from the vasculature. Be- 
cause normal endothelial cells release NO and this 
NO may prevent leukocytes from adhering to endo- 
thelial cells, it is possible that reduced basal NO 
release after reperfusion may promote or allow 
neutrophil adherence to endothelial cells, resulting 
in neutrophil-induced reperfusion i jury. Kubes and 
Granger 27 have shown that infusion of specific in- 
hibitors of NO synthesis, such as NG-monomethyl - 
L-arginine (L-NMMA) or No)-nitro-L-arginine 
methyl ester (L-NAME), promotes neutrophil adhe- 
sion in postcapillary venules through a CD11/ 
CD18-dependent mechanism. Lefer, Nakanishi, 
and Vinten-Johansen 2s recently demonstrated that 
infusion of the NO precursor L-arginine at the time 
of reperfusion dramatically reduces the extent of 
neutrophil-mediated myocardial and endothelial 
cell injury in dogs. 
Second, NO maintains vasomotor function and 
may decrease pulmonary edema in lung injury. Lung 
ischemia and reperfusion are associated with a 
decreased release of endothelial NO and prostacy- 
clin synthesis. Both of these molecules are potent 
modulators of pulmonary vasomotor tone. In a lung 
injury model Kavanagh and associates 29 demon- 
strated that pretreatment with inhaled NO (90 to 
120 ppm) reduced pulmonary artery pressure and 
precapillary PVR in addition to decreasing pulmo- 
nary capillary filtration coefficient. Xiong and asso- 
ciates 3° reported that maintaining NO levels by 
administration of the NO precursor L-arginine abol- 
ished the increase in microvascular permeability in
isolated rat lungs. 
In addition, NO has a strong antiplatelet effect. 
NO has been shown to block platelet aggregation 
and to reduce platelet adhesion to endothelial cell 
monolayers.3, 7, 8 The platelet activating factor an- 
tagonist CM3988 has been shown to improve post- 
transplant lung allograft function. 3~ Although we 
did not measure platelet function in these experi- 
merits, it is possible that NO may have a similar 
antiplatelet effect on preserved lung allografts. 
Unfortunately, delayed administration of NO 
could not reverse the severe lung allograft reperfu- 
sion injury. Gas exchange and the degree of neutro- 
phil sequestration i  the allograft was not affected 
by delayed inhalation of NO. It is possible that in the 
presence of such severe injury inhaled NO may be 
rapidly inactivated by interstitial or alveolar edema 
fluid. This might explain its lack of effect apart from 
modest vasodilation. In human lung allografts we 
have recently demonstrated that inhaled NO does 
improve gas exchange and pulmonary hemodynam- 
ics of early allograft dysfunction. 32It is possible that 
the injury in this model (18-hour ischemic time) was 
so severe as to enable any beneficial effect as 
observed in human allografts having a shorter isch- 
emic time (4 to 8 hours). 
In summary, we have demonstrated that inhaled 
NO when administered from the onset of reperfu- 
sion reduces the severe lung injury expected after 
prolonged allograft storage. The mechanism of this 
effect is uncertain but likely is a result of a combi- 
nation of the known vasodilatory and antineutrophil 
adhesion effects of NO. 
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